Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Amalyte Pharmaceuticals
San Francisco, California, United States
- Ownership
- Private
- Development stage
- Other
01
Overview
Amalyte Pharmaceuticals was a clinical-stage biotechnology company focused on developing therapies for metabolic and inflammatory diseases. The company's lead asset was MBX-2982, an oral, potent, and selective agonist of G protein-coupled receptor 119 (GPR119). Amalyte was specifically advancing MBX-2982 for its potential to prevent hypoglycemia in patients with type 1 diabetes by enhancing the secretion of glucagon-like peptide-1 (GLP-1) and other incretins. In October 2019, Amalyte was acquired by CymaBay Therapeutics, which sought to re-integrate MBX-2982 into its own clinical pipeline.
- Therapeutic areas
- Endocrinology
- Modalities
- Small molecule
- Industry
- Biotech
02
Partnerships
CymaBay Therapeutics
Beyond the preview
Go deeper on Amalyte Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Amalyte Pharmaceuticals.